Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity

Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity

Drug resistance and tumor heterogeneity limits the therapeutic efficacy in treating glioblastoma, an aggressive infiltrative type of brain tumor. GBM cells develops resistance against chemotherapeutic agent, temozolomide (TMZ), which leads to the failure in treatment strategies. This enduring challe...

Full description

Bibliographic Details
Main Authors: Phuong Doan, Phung Nguyen, Akshaya Murugesan, Nuno R. Candeias, Olli Yli-Harja, Meenakshisundaram Kandhavelu
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cells
Subjects:
glioblastoma
mesenchymal GBM
alkylaminophenol
GPR17 agonist
synergy
cell cycle arrest
Online Access:https://www.mdpi.com/2073-4409/10/8/1975

Internet

https://www.mdpi.com/2073-4409/10/8/1975

Similar Items